United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating Officer, John Onopchenko.
View HTML
Toggle Summary Endologix, Inc. to Present at the Stifel 2017 Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the Stifel 2017 Healthcare
View HTML
Toggle Summary Endologix Appoints John Onopchenko as Chief Operating Officer
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating Officer, effective October 30, 2017 . Mr.
View HTML
Toggle Summary Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market close on Tuesday, November 7, 2017 .
View HTML
Toggle Summary Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix® EndoVascular Aneurysm Sealing System
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration (" FDA ") to commence
View HTML
Toggle Summary Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the CE Mark approval for its Nellix ® EndoVascular Aneurysm Sealing System ("Nellix") with the refined Indications for Use (IFU).
View HTML
Toggle Summary Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd.
View HTML
Toggle Summary Endologix Announces Positive Clinical Results from the LEOPARD Clinical Study
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD ( L ooking at  E var  O utcomes by  P rimary  A nalysis of  R andomized  D ata) clinical study.
View HTML
Toggle Summary Endologix Reports Second Quarter 2017 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2017 . "While we are pleased with the overall results in the second quarter, the recovery
View HTML
Toggle Summary Endologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2017 after the market close on Wednesday, August 2, 2017 .
View HTML
Toggle Summary Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the Canaccord Genuity 37th Annual
View HTML
Toggle Summary Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the presentation of two-year clinical data from the Company's Nellix® EVAS FORWARD IDE trial that prospectively enrolled patients with abdominal
View HTML
Toggle Summary Endologix Reports Positive Clinical Data from the Ovation LUCY Study
First Prospective Clinical Trial to Evaluate Endovascular Aneurysm Repair (EVAR) in Women IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced 30-day results from the LUCY (Evaluation of Fema L es
View HTML
Toggle Summary Endologix Provides an Update on the Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status
Company to Host an Investor Conference Call on May 18, 2017 at 7:30 a.m. ET IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administration (FDA)
View HTML
Toggle Summary Endologix Reports First Quarter 2017 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017 . "We are pleased with our progress during the quarter and our solid start to the
View HTML